1 completed, 1 recruiting. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow Maximum Tolerated Dose: new trials by email Literature Review of Maximum Tolerated Dose trials Research Report on Maximum Tolerated Dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) PK-optimized oral hydroxyurea at MTD until 15 years of age. - Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0) | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 50 | 2024-12-19 | 2025-09-16 |
| COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure SGLT2i, beta blocker, ARNI, MRA, MTD, Education-First - Heart Failure | Phase 4 | Completed | Brigham and Women's Hospital | 503 | 2023-05-05 | 2026-02-06 |
Anemia, Sickle Cell (1) · Heart Failure (1)
Brigham and Women's Hospital (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (2)
Charles T. Quinn, Professor of Pediatrics, M.D., M.S. (1)